The complexity of sunitinib dosing in renal cell cancer patients

Por Desar, Ingrid M.E., Mulder, Sasja F., Mulders, Peter F.A., van Herpen, Carla M.L.
Publicado no Transl Androl Urol (2012)

Theranostic applications of antibodies in oncology

Por Fleuren, Emmy D.G., Versleijen-Jonkers, Yvonne M.H., Heskamp, Sandra, van Herpen, Carla M.L., Oyen, Wim J.G., van der Graaf, Winette T.A., Boerman, Otto C.
Publicado no Mol Oncol (2014)

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study

Por van Boxtel, Wim, Lütje, Susanne, van Engen-van Grunsven, Ilse C.H., Verhaegh, Gerald W., Schalken, Jack A., Jonker, Marianne A., Nagarajah, James, Gotthardt, Martin, van Herpen, Carla M.L.
Publicado no Theranostics (2020)

Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

Por Mulder, Sasja F, Bertens, Dirk, Desar, Ingrid ME, Vissers, Kris CP, Mulders, Peter FA, Punt, Cornelis JA, van Spronsen, Dick-Johan, Langenhuijsen, Johan F, Kessels, Roy PC, van Herpen, Carla ML
Publicado em 2014

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor

Por Küsters-Vandevelde, Heidi VN, Willemsen, Annelieke ECAB, Groenen, Patricia JTA, Küsters, Benno, Lammens, Martin, Wesseling, Pieter, Djafarihamedani, Melika, Rijntjes, Jos, Delye, Hans, Willemsen, Michel A, van Herpen, Carla ML, Blokx, Willeke AM
Publicado em 2014

Merkel Cell Carcinoma: New Trends

Por Zwijnenburg, Ellen M., Lubeek, Satish F.K., Werner, Johanna E.M., Amir, Avital L., Weijs, Willem L.J., Takes, Robert P., Pegge, Sjoert A.H., van Herpen, Carla M.L., Adema, Gosse J., Kaanders, Johannes H. A. M.
Publicado no Cancers (Basel) (2021)

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue

Por Prinsen, Hetty, van Laarhoven, Hanneke WM, Pots, Jeanette M, Duiveman-de Boer, Tjitske, Mulder, Sasja F, van Herpen, Carla ML, Jacobs, Joannes FM, Leer, Jan Willem H, Bleijenberg, Gijs, Stelma, Foekje F, Torensma, Ruurd, de Vries, I Jolanda M
Publicado no Hum Vaccin Immunother (2015)

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

Por van Herpen, Carla M.L., Agarwala, Sanjiv S., Hauschild, Axel, Berking, Carola, Beck, J. Thaddeus, Schadendorf, Dirk, Jansen, Rob, Queirolo, Paola, Ascierto, Paolo A., Blank, Christian U., Heinrich, Michael C., Pal, Rupam R., Derti, Adnan, Antona, Victor, Nauwelaerts, Heidi, Zubel, Angela, Dummer, Reinhard
Publicado no Oncotarget (2019)

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

Por Lesterhuis, W. Joost, Punt, Cornelis J.A., Hato, Stanleyson V., Eleveld-Trancikova, Dagmar, Jansen, Bastiaan J.H., Nierkens, Stefan, Schreibelt, Gerty, de Boer, Annemiek, Van Herpen, Carla M.L., Kaanders, Johannes H., van Krieken, Johan H.J.M., Adema, Gosse J., Figdor, Carl G., de Vries, I. Jolanda M.
Publicado em 2011

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity

Por Hato, Stanleyson V., Figdor, Carl G., Takahashi, Susumu, Pen, Anja E., Halilovic, Altuna, Bol, Kalijn F., Vasaturo, Angela, Inoue, Yukie, de Haas, Nienke, Verweij, Dagmar, Van Herpen, Carla M.L., Kaanders, Johannes H., van Krieken, Johan H.J.M., Van Laarhoven, Hanneke W.M., Hooijer, Gerrit K.J., Punt, Cornelis J.A., Asai, Akira, de Vries, I. Jolanda M., Lesterhuis, W.J.
Publicado no Oncotarget (2017)